Placebo News and Research

RSS

Drinking beetroot juice improves sprint performance and decision-making during exercise

Rugby players take note: drinking high nitrate beetroot juice improves both sprint performance and decision-making during prolonged intermittent exercise such as rugby and football, according to scientists from the University of Exeter.

19 Sep 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression.

16 Sep 2015

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Johns Hopkins University researchers have received an estimated $7.5 million National Institutes of Health grant to clinically test what would be the first treatment to prevent or delay the onset of Alzheimer's dementia.

16 Sep 2015

Fusion IONZ’s non-thermal far infrared technology successfully passes board certified clinical trial

Fusion IONZ has successfully commissioned and passed a three phase human clinical trial. This clinical trial was conducted by the Dr. Lisa Tully and the Energy Medicine Research Institute.

15 Sep 2015

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes.

15 Sep 2015

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.

15 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

Modified Story Memory Technique improves memory in adults with moderate to severe TBI

Kessler Foundation researchers published results of a randomized clinical trial (RCT) of a cognitive intervention to improve learning and memory in individuals with traumatic brain injury (TBI) - the TBI-MEM trial.

11 Sep 2015

NIH-funded study may help predict treatment response in older adults with depression

Treating depressed individuals and figuring out who will and won't respond to antidepressants is mostly trial and error — much to the frustration of patients and the health care providers who treat them.

11 Sep 2015

Nicotine reinforcement demonstrated in study with ‘never-smokers’

In a study with 18 adults who had never smoked, scientists at Johns Hopkins report they have demonstrated one of the earliest steps — nicotine “reinforcement” — in the process of addiction, and shown that some people are far more vulnerable to nicotine addiction than others.

10 Sep 2015

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that the first patient has been dosed in a newly initiated long term-safety extension study of Resolaris for adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments.

10 Sep 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Study points to genetic/metabolic factors that make people vulnerable to nicotine addiction

In a study with 18 adults who had never smoked, scientists at Johns Hopkins report they have demonstrated one of the earliest steps — nicotine "reinforcement" — in the process of addiction, and shown that some people are far more vulnerable to nicotine addiction than others.

10 Sep 2015

National Association Of Science Writers Announces 2015 Science In Society Award Winners

Winners in each category receive a cash prize of $2,500, to be awarded at a reception on October 10, 2015, at the ScienceWriters2015 meeting taking place this year in Cambridge, Mass.

10 Sep 2015

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome that causes major disruption in several areas of life for many women. Many treatment options have been proposed, but which are most effective? A comprehensive review of the evidence, including specific treatment guidelines, is presented in the September Journal of Psychiatric Practice, published by Wolters Kluwer.

9 Sep 2015

Upfront combination therapy fulfils AMBITION in PAH patients

Upfront treatment with the combination of ambrisentan and tadalafil improves outcomes in patients with pulmonary arterial hypertension more than either treatment as monotherapy, shows a randomised trial.

9 Sep 2015

Botulinum toxin A improves muscle tone in hemiparesis

A single injection of abobotulinumtoxinA into upper limb muscles significantly reduces muscle tone in patients with hemiparesis following stroke or traumatic brain injury, study findings show.

9 Sep 2015

PAH treatments less effective in CTD-associated disease

Patients with connective tissue disease-associated pulmonary arterial hypertension have a poorer response to advanced PAH treatments than those with idiopathic disease, finds a meta-analysis.

9 Sep 2015

Riluzole ‘a candidate treatment’ for cerebellar ataxia

Riluzole may be an effective treatment for cerebellar ataxia, say researchers who call for further studies to confirm their findings.

9 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

Placebo News and Research

Drinking beetroot juice improves sprint performance and decision-making during exercise

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Fusion IONZ’s non-thermal far infrared technology successfully passes board certified clinical trial

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Modified Story Memory Technique improves memory in adults with moderate to severe TBI

NIH-funded study may help predict treatment response in older adults with depression

Nicotine reinforcement demonstrated in study with ‘never-smokers’

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Study points to genetic/metabolic factors that make people vulnerable to nicotine addiction

National Association Of Science Writers Announces 2015 Science In Society Award Winners

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Upfront combination therapy fulfils AMBITION in PAH patients

Botulinum toxin A improves muscle tone in hemiparesis

PAH treatments less effective in CTD-associated disease

Riluzole ‘a candidate treatment’ for cerebellar ataxia

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News